Trial Profile
A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS- 986141 For the Prevention of Recurrent Brain Infarction in Subjects Receiving Acetylsalicylic Acid (ASA) Following Acute Ischemic Stroke or Transient Ischemic Attack
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs BMS 986141 (Primary) ; Aspirin
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Dec 2018 Status changed from discontinued to completed.
- 16 May 2018 Status has been changed to discontinued.
- 04 Mar 2017 This trial has been discontinued in Spain.